Quest Diagnostics Director Robert Carter Acquires 3,864 Shares Through Dividend Reinvestment Plan

Director's Share Acquisition Through Automated Dividend Reinvestment

Robert B. Carter, who serves as a director on the board of Quest Diagnostics, completed a share acquisition on July 22, 2026, acquiring 3,864 shares of the company's common stock. The shares were obtained at a price of $206.804 per share, totaling approximately $800,000 in share value based on the stated transaction price. The acquisition was conducted through a dividend reinvestment plan, a mechanism that automatically converts cash dividend payments into additional company shares at the prevailing market price.

Dividend reinvestment plans, commonly known as DRIPs, are standard mechanisms offered by publicly traded companies to enable shareholders to automatically purchase additional shares using their dividend distributions. The filing indicates that Carter's broker administered the plan, and the shares acquired through this method were eligible for deferred reporting under Rule 16a-6. Carter elected to report the transaction early on Form 4 rather than waiting for the standard Form 5 filing deadline, demonstrating transparency in disclosing insider transactions to investors and regulators.

Transaction Details and Settlement Information

The transaction occurred on July 22, 2026, with the regulatory disclosure filed five days later on July 27, 2026. The filing was executed by Sean D. Mersten, an attorney-in-fact representing Robert B. Carter, in accordance with standard insider trading disclosure protocols. Carter's principal residence is listed as 500 Plaza Drive, Secaucus, New Jersey, and he is identified solely by his board position as a director of Quest Diagnostics, with no additional officer titles noted in the filing.

The transaction code designation in the filing indicates this was a standard acquisition of non-derivative securities, meaning Carter purchased actual Quest Diagnostics common shares rather than derivative instruments such as options or warrants. The shares are held in direct ownership form, indicating Carter maintains beneficial ownership rights and voting power over the acquired securities. No derivative securities transactions or adjustments to existing derivative holdings were reported in connection with this transaction.

Beneficial Ownership Position Following the Acquisition

Following the reported transaction, Carter's total beneficial ownership of Quest Diagnostics common stock stands at 3,864 shares. The filing indicates that this represents the complete beneficial ownership position following the July 22 transaction, though the document does not disclose Carter's prior share count before this acquisition. Investors seeking detailed historical ownership information would need to cross-reference prior Form 4 filings or the company's proxy statements to determine the magnitude of change in his position.

The direct ownership structure means that Carter has full beneficial interest in the 3,864 shares, including voting rights at shareholder meetings and entitlement to any future dividend distributions. No indirect ownership arrangements, such as holdings through trusts, family entities, or other vehicles, were reported in connection with these shares. This straightforward ownership structure is typical for board members maintaining personal investment positions in the companies they oversee.

Insider Trading Compliance and Early Reporting Election

The filing includes a specific notation explaining that the transaction reflects shares acquired pursuant to a dividend reinvestment plan and that such shares would normally be eligible for deferred reporting on Form 5 under Rule 16a-6. Rule 16a-6 permits certain automatic dividend reinvestment transactions to be reported on the less frequent Form 5 filing, which is typically filed within 45 days after the fiscal year end. Carter's decision to report this transaction on Form 4, which requires filing within two business days of the transaction, represents an earlier disclosure than technically required by regulation.

This early voluntary reporting approach demonstrates Carter's approach to insider trading transparency. While the SEC provides safe harbor provisions for dividend reinvestment plans to reduce administrative burden on traders and issuers, many insiders and their legal counsel choose to file Form 4 immediately to provide market participants with timely notice of share acquisitions by company insiders. The early filing may signal confidence in the transaction or reflect internal compliance procedures requiring immediate disclosure of all insider transactions regardless of the regulatory safe harbor available.

Quest Diagnostics Board Composition and Director Role

Robert B. Carter holds the position of director at Quest Diagnostics, one of the nation's largest diagnostic services companies. The company provides clinical laboratory testing, drug screening, and health and wellness services to patients, employers, hospitals, and healthcare providers across the United States. Directors at major publicly traded companies like Quest Diagnostics are responsible for overseeing corporate strategy, financial performance, risk management, and executive compensation, among other fiduciary duties. Carter's continued investment in Quest Diagnostics shares through dividend reinvestment may reflect his confidence in the company's business trajectory and financial performance.

Board membership at large-cap healthcare and diagnostics companies involves significant ongoing responsibilities, including attendance at regular and special board meetings, participation on board committees, and engagement with management on key business initiatives. Directors typically maintain personal investments in their companies as part of standard board practices and sometimes as required by governance guidelines. The acquisition of additional shares through automatic dividend reinvestment demonstrates Carter's ongoing capital commitment to Quest Diagnostics beyond his board-level involvement with the company.

Market Context for the Acquisition Price

The shares were acquired at a price of $206.804 per share, reflecting the valuation at which Carter's dividends were converted into additional shares on July 22, 2026. This price represents the closing or trading price of Quest Diagnostics common stock on that date, as the dividend reinvestment mechanism would have utilized the market price available on the transaction settlement date. Investors comparing this price to current or historical trading levels may gain insight into the company's stock performance relative to the acquisition date.

The filing does not provide commentary on whether Carter views the acquisition price as favorable relative to the company's intrinsic value or future prospects. The automatic nature of dividend reinvestment means that purchases occur regardless of whether the insider considers the current price attractive or expensive. This systematic investment approach, when employed by company insiders, can be viewed by some investors as a neutral indicator of confidence, since the insider is committed to the reinvestment process regardless of short-term stock price fluctuations.

Regulatory Requirements and Insider Trading Disclosure Standards

Form 4 filings are required under Section 16 of the Securities Exchange Act of 1934 for directors, officers, and beneficial owners of more than 10 percent of a company's securities. These filings must be submitted within two business days of the transaction occurring. The form provides the SEC, company management, and investors with contemporaneous disclosure of trading activity by company insiders, enabling market participants to assess whether insiders are buying or selling shares and at what prices. This transparency is intended to reduce information asymmetries and help prevent insider trading abuses.

Quest Diagnostics, as a NASDAQ-listed company, is subject to SEC reporting requirements and must ensure that all covered insiders comply with Form 4 filing obligations. The company's transfer agent and insider trading compliance program would typically monitor dividend reinvestment activities and ensure that appropriate Form 4 filings are generated on a timely basis. Carter's filing, executed through his attorney-in-fact, follows standard procedures for insider trading disclosure and includes all required information elements regarding the security acquired, transaction date, price, and resulting beneficial ownership.

Dividend Reinvestment Plan Mechanics and Investor Participation

Dividend reinvestment plans operate by automatically converting cash dividend distributions into additional shares of company stock at the market price prevailing on the dividend reinvestment date. Rather than receiving dividend payments in cash, participating shareholders see their dividend amounts used to purchase additional shares at the trading price available on the transaction date. For many long-term investors, including company insiders and board members, dividend reinvestment can be an attractive way to compound returns over time without the need for active decision-making on dividend deployment.

The filing specifies that Carter's broker administered the DRIP, meaning the brokerage firm handling Carter's investment account manages the mechanics of converting dividends into shares. Many brokerage firms offer dividend reinvestment plans as a standard service to their clients, and the plans are typically available at no additional commission or fee to participating investors. For insiders like Carter, utilizing a broker-administered DRIP provides a systematic and transparent method of reinvesting distributions while maintaining clear documentation for regulatory compliance purposes.

Transparency and Future Insider Transaction Monitoring

This transaction disclosure contributes to the ongoing record of insider trading activity at Quest Diagnostics that is publicly available through the SEC's EDGAR database and various financial data providers. Investors interested in tracking insider buying and selling patterns can review aggregated data on insider transactions to assess whether company leadership and board members are net buyers or sellers of company shares. Repeated insider purchases, whether through automatic dividend reinvestment or open market acquisitions, may be interpreted by some investors as a positive indicator of insider confidence in the company's prospects.

The filing remains permanently accessible in the SEC's public records and is searchable by company name, insider name, and transaction date. Investors, analysts, and corporate governance advocates regularly monitor insider transaction filings to identify patterns or trends in executive and director trading. While a single dividend reinvestment transaction may have limited interpretive value, a pattern of accumulation across multiple insiders or time periods may provide meaningful signals to the investment community regarding management's assessment of shareholder value and the company's strategic direction.